ADAP – Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plcADAP
$0.245Name : Adaptimmune Therapeutics plc
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $64,937,740.00
EPSttm : -0.3
Adaptimmune Therapeutics plc
$0.245
1.16%$0.0028Float Short %
2
Margin Of Safety %
Put/Call OI Ratio
0.01
EPS Next Q Diff
0.08
EPS Last/This Y
-0.2
EPS This/Next Y
0.01
Price
0.24
Target Price
1.44
Analyst Recom
2.5
Performance Q
11.36
Relative Volume
0.67
Beta
2.21
Ticker: ADAP
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-06-02 | ADAP | 0.2851 | 0.01 | 0.00 | 3240 |
| 2025-06-03 | ADAP | 0.2859 | 0.01 | 0.00 | 3240 |
| 2025-06-04 | ADAP | 0.2889 | 0.01 | 0.00 | 3281 |
| 2025-06-05 | ADAP | 0.287 | 0.01 | 0.00 | 3314 |
| 2025-06-06 | ADAP | 0.283 | 0.01 | 0.00 | 3314 |
| 2025-06-09 | ADAP | 0.2825 | 0.01 | 0.00 | 3322 |
| 2025-06-10 | ADAP | 0.2772 | 0.01 | 0.00 | 3325 |
| 2025-06-11 | ADAP | 0.2723 | 0.01 | 0.00 | 3336 |
| 2025-06-12 | ADAP | 0.2465 | 0.01 | 0.00 | 3341 |
| 2025-06-13 | ADAP | 0.2453 | 0.01 | 0.50 | 3341 |
| 2025-06-16 | ADAP | 0.2597 | 0.01 | 0.00 | 3344 |
| 2025-06-17 | ADAP | 0.256 | 0.01 | 0.00 | 3328 |
| 2025-06-18 | ADAP | 0.2564 | 0.01 | 0.21 | 3330 |
| 2025-06-20 | ADAP | 0.2561 | 0.01 | 0.00 | 3351 |
| 2025-06-23 | ADAP | 0.2437 | 0.01 | 0.00 | 2228 |
| 2025-06-24 | ADAP | 0.2536 | 0.01 | 0.00 | 2237 |
| 2025-06-25 | ADAP | 0.2522 | 0.01 | 0.00 | 2238 |
| 2025-06-26 | ADAP | 0.2416 | 0.01 | 0.00 | 2241 |
| 2025-06-27 | ADAP | 0.2407 | 0.01 | 0.06 | 2312 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-06-02 | ADAP | 0.28 | -156.2 | - | -0.50 |
| 2025-06-03 | ADAP | 0.29 | -156.2 | - | -0.50 |
| 2025-06-04 | ADAP | 0.29 | -156.2 | - | -0.50 |
| 2025-06-05 | ADAP | 0.29 | -156.2 | - | -0.50 |
| 2025-06-06 | ADAP | 0.28 | -156.2 | - | -0.50 |
| 2025-06-09 | ADAP | 0.28 | -156.2 | - | -0.50 |
| 2025-06-10 | ADAP | 0.28 | -156.2 | - | -0.50 |
| 2025-06-11 | ADAP | 0.27 | -156.2 | - | -0.50 |
| 2025-06-12 | ADAP | 0.25 | -156.2 | - | -0.50 |
| 2025-06-13 | ADAP | 0.24 | -156.2 | - | -0.50 |
| 2025-06-16 | ADAP | 0.26 | -156.2 | - | -0.50 |
| 2025-06-17 | ADAP | 0.26 | -156.2 | - | -0.50 |
| 2025-06-18 | ADAP | 0.26 | -156.2 | - | -0.50 |
| 2025-06-20 | ADAP | 0.25 | -156.2 | - | -0.50 |
| 2025-06-23 | ADAP | 0.24 | -156.2 | - | -0.50 |
| 2025-06-24 | ADAP | 0.26 | -156.2 | - | -0.50 |
| 2025-06-25 | ADAP | 0.25 | -156.2 | - | -0.50 |
| 2025-06-26 | ADAP | 0.24 | -156.2 | - | -0.50 |
| 2025-06-27 | ADAP | 0.24 | -156.2 | - | -0.50 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-06-02 | ADAP | -0.62 | -22.49 | 2.55 |
| 2025-06-03 | ADAP | -0.62 | -22.49 | 2.55 |
| 2025-06-04 | ADAP | -0.62 | -22.49 | 2.55 |
| 2025-06-05 | ADAP | -0.62 | -22.49 | 2.55 |
| 2025-06-06 | ADAP | -0.62 | -22.49 | 2.55 |
| 2025-06-09 | ADAP | -0.62 | -22.49 | 2.55 |
| 2025-06-10 | ADAP | -0.62 | -22.49 | 2.55 |
| 2025-06-11 | ADAP | -0.62 | -22.49 | 2.34 |
| 2025-06-12 | ADAP | -0.62 | -22.49 | 2.34 |
| 2025-06-13 | ADAP | -0.62 | -22.49 | 2.34 |
| 2025-06-16 | ADAP | -0.62 | -22.51 | 2.34 |
| 2025-06-18 | ADAP | -0.62 | -22.51 | 2.34 |
| 2025-06-20 | ADAP | -0.62 | -22.51 | 2.34 |
| 2025-06-23 | ADAP | -0.62 | -22.55 | 2.34 |
| 2025-06-24 | ADAP | -0.62 | -22.55 | 2.34 |
| 2025-06-25 | ADAP | -0.62 | -22.55 | 2.34 |
| 2025-06-26 | ADAP | -0.62 | -22.55 | 2.00 |
| 2025-06-27 | ADAP | -0.62 | -22.55 | 2.00 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.18
Avg. EPS Est. Current Quarter
-0.14
Avg. EPS Est. Next Quarter
-0.1
Insider Transactions
-0.62
Institutional Transactions
-22.55
Beta
2.21
Average Sales Estimate Current Quarter
11
Average Sales Estimate Next Quarter
14
Fair Value
Quality Score
25
Growth Score
56
Sentiment Score
19
Actual DrawDown %
97.8
Max Drawdown 5-Year %
-98.2
Target Price
1.44
P/E
Forward P/E
PEG
P/S
0.35
P/B
P/Free Cash Flow
EPS
-0.27
Average EPS Est. Cur. Y
-0.5
EPS Next Y. (Est.)
-0.49
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-38.56
Relative Volume
0.67
Return on Equity vs Sector %
162.8
Return on Equity vs Industry %
180.7
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.01
EBIT Estimation
Adaptimmune Therapeutics plcSector: Healthcare
Industry: Biotechnology
Employees: 506
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatment synovial sarcoma and myxoid liposarcoma; and ADP-5701, which is in Phase 1 clinical trial for the treatment of head and neck cancer. The company also focuses on the development of T-cell therapies directed to PRAME (ADP-600) and CD70 (ADP-520). It has strategic collaboration with Galapagos to clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel produced on Galapagos' decentralized manufacturing platform (ADP-5701) in patients with head and neck cancer; collaboration and license agreement with Noile-Immune Biotech, Inc. and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
stock quote shares ADAP – Adaptimmune Therapeutics plc Stock Price stock today
news today ADAP – Adaptimmune Therapeutics plc stock forecast ,stock prediction 2023 2024 2025
marketwatch ADAP – Adaptimmune Therapeutics plc yahoo finance google finance
stock history ADAP – Adaptimmune Therapeutics plc invest stock market
stock prices ADAP premarket after hours
ticker ADAP fair value insiders trading